Novo Nordisk Halts Two Cardiovascular Trials of Inflammation-Targeting Drug
Source Summary
Novo Nordisk has discontinued two clinical trials of a drug designed to reduce inflammation and improve cardiovascular health. The company's decision represents another setback for the anti-inflammatory approach to treating cardiovascular disease.
Why it matters
The trial stoppage signals continued challenges in developing anti-inflammatory treatments for cardiovascular disease, a major therapeutic area for pharmaceutical companies.
